Use of Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Risk of Dementia in Heart Failure

American Journal of Alzheimer's Disease and other Dementias

Volumn 31, Issue 5, 2016, Pages 395-404

  Chitnis, Abhishek S ^a   Aparasu, Rajender R ^b   Chen, Hua ^b   Kunik, Mark E ^c,d   Schulz, Paul E ^e   Johnson, Michael L ^b  

^a EVIDERA   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS   (United States)

Author keywords

angiotensin receptor blockers; angiotensin converting enzyme inhibitors; dementia; heart failure

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; DEMENTIA; DRUG EFFECT; DRUG USE; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; RISK ASSESSMENT; STRUCTURAL MODEL; VERY ELDERLY; RISK; STATISTICAL MODEL;

AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DEMENTIA; FEMALE; HEART FAILURE; HUMANS; LONGITUDINAL STUDIES; MALE; MODELS, STATISTICAL; RETROSPECTIVE STUDIES; RISK;

EID: 84978250325     PISSN: 15333175     EISSN: 19382731     Source Type: Journal    
DOI: 10.1177/1533317515618799     Document Type: Article

References (45)

1. Qiu C, Winblad B, Marengoni A, Klarin I, Fastbom J, Fratiglioni L,. Heart failure and risk of dementia and Alzheimer disease: a population-based cohort study. Arch Intern Med. 2006; 166 (9): 1003-1008.
2. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation. 2012; 125 (1): e2-e220.
3. Heckman GA, Patterson CJ, Demers C, St Onge J, Turpie ID, McKelvie RS,. Heart failure and cognitive impairment: challenges and opportunities. Clin Intervent Aging. 2007; 2 (2): 209-218.
4. Ahluwalia SC, Gross CP, Chaudhry SI, et al. Impact of comorbidity on mortality among older persons with advanced heart failure. J Gen Intern Med. 2012; 27 (5): 513-519.
5. Braunstein JB, Anderson GF, Gerstenblith G, et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol. 2003; 42 (7): 1226-1233.
6. Chaudhry SI, Wang Y, Gill TM, Krumholz HM,. Geriatric conditions and subsequent mortality in older patients with heart failure. J Am Coll Cardiol. 2010; 55 (4): 309-316.
7. Alonso A, Mosley TH Jr, Gottesman RF, Catellier D, Sharrett AR, Coresh J,. Risk of dementia hospitalisation associated with cardiovascular risk factors in midlife and older age: the Atherosclerosis Risk in Communities (ARIC) study. J Neurol Neurosurg Psychiatry. 2009; 80 (11): 1194-1201.
8. Wenger NK, Scheidt S, Weber M,. Cardiovascular risk factors, cardiovascular disease, cardiovascular drug therapies, and dementia/cognitive dysfunction: how do the pieces of the puzzle fit together? Am J Geriatr Cardiol. 2007; 16 (3): 133-135.
9. Kumari U, Heese K,. Cardiovascular dementia-a different perspective. Open Biochem J. 2010; 4: 29-52.
10. Johnson ML, Parikh N, Kunik ME, et al. Antihypertensive drug use and the risk of dementia in patients with diabetes mellitus. Alzheimers Dement. 2012; 8 (5): 437-444.
11. Parikh NM, Morgan RO, Kunik ME, et al. Risk factors for dementia in patients over 65 with diabetes. Int J Geriatr Psychiatry. 2011; 26 (7): 749-757.
12. Shah K, Qureshi SU, Johnson M, Parikh N, Schulz PE, Kunik ME,. Does use of antihypertensive drugs affect the incidence or progression of dementia? A systematic review. Am J Geriatr Pharmacother. 2009; 7 (5): 250-261.
13. Frishman WH,. Are antihypertensive agents protective against dementia? A review of clinical and preclinical data. Heart Dis. 2002; 4 (6): 380-386.
14. Hanes DS, Weir MR,. Usefulness of ARBs and ACE inhibitors in the prevention of vascular dementia in the elderly. Am J Geriatr Cardiol. 2007; 16 (3): 175-182.
15. Kehoe PG, Wilcock GK,. Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease? Lancet Neurol. 2007; 6 (4): 373-378.
16. Khachaturian AS, Zandi PP, Lyketsos CG, et al. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch Neurol. 2006; 63 (5): 686-692.
17. Peters R, Beckett N, Forette F, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol. 2008; 7 (8): 683-689.
18. Zuccala G, Onder G, Marzetti E, et al. Use of angiotensin-converting enzyme inhibitors and variations in cognitive performance among patients with heart failure. Eur Heart J. 2005; 26 (3): 226-233.
19. Hernan MA, Brumback B, Robins JM,. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000; 11 (5): 561-570.
20. Desai RJ, Ashton CM, Deswal A, et al. Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure. Pharmacoepidemiol Drug Saf. 2012; 21 (3): 233-240.
21. Robins JM, Hernan MA, Brumback B,. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000; 11 (5): 550-560.
22. Little RJA, Rubin DB,. The analysis of social science data with missing values. Soc Methods Res. 1989; 18 (2-3): 292-326.
23. Trewet CB, Shireman TI, Rigler SK, Howard PA,. Do ACE Inhibitors/Angiotensin II type 1 receptor antagonists reduce hospitalisations in older patients with heart failure? A propensity analysis. Drugs Aging. 2007; 24 (11): 945-955.
24. Deswal A, Petersen NJ, Souchek J, Ashton CM, Wray NP,. Impact of race on health care utilization and outcomes in veterans with congestive heart failure. J Am Coll Cardiol. 2004; 43 (5): 778-784.
25. Chitnis AS, Aparasu RR, Chen H, Johnson ML,. Effect of certain angiotensin-converting enzyme inhibitors on mortality in heart failure: a multiple-propensity analysis. Res Soc Adm Pharm. 2012; 8 (2): 145-156.
26. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC,. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin. 2009; 25 (9): 2303-2310.
27. Chitnis AS, Aparasu RR, Chen H, Johnson ML,. Comparative effectiveness of different angiotensin-converting enzyme inhibitors on the risk of hospitalization in patients with heart failure. J Comp Eff Res. 2012; 1 (2): 195-206.
28. Linden A, Adams JL,. Evaluating health management programmes over time: application of propensity score-based weighting to longitudinal data. J Eval Clin Pract. 2010; 16 (1): 180-185.
29. Rubin DB,. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997; 127 (8 pt 2): 757-763.
30. Johnson ML, Bush RL, Collins TC, et al. Propensity score analysis in observational studies: outcomes after abdominal aortic aneurysm repair. Am J Surg. 2006; 192 (3): 336-343.
31. Hernan MA, Brumback BA, Robins JM,. Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures. Stat Med. 2002; 21 (12): 1689-1709.
32. Ray WA,. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003; 158 (9): 915-920.
33. Hernandez AF, Harrington RA,. Comparative effectiveness of angiotensin-converting-enzyme inhibitors: is an ACE always an ace? CMAJ. 2008; 178 (10): 1316-1319.
34. Rozzini L, Chilovi BV, Bertoletti E, et al. Angiotensin converting enzyme (ACE) inhibitors modulate the rate of progression of amnestic mild cognitive impairment. Int J Geriatr Psychiatry. 2006; 21 (6): 550-555.
35. Kehoe PG, Passmore PA,. The renin-angiotensin system and antihypertensive drugs in Alzheimer's disease: current standing of the angiotensin hypothesis? J Alzheimers Dis. 2012; 30 (suppl 2): S251-S268.
36. Eriksson SV, Eneroth P, Kjekshus J, Offstad J, Swedberg K,. Neuroendocrine activation in relation to left ventricular function in chronic severe congestive heart failure: a subgroup analysis from the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). Clin Cardiol. 1994; 17 (11): 603-606.
37. Lindley TE, Doobay MF, Sharma RV, Davisson RL,. Superoxide is involved in the central nervous system activation and sympathoexcitation of myocardial infarction-induced heart failure. Circ Res. 2004; 94 (3): 402-409.
38. Ohrui T, Tomita N, Sato-Nakagawa T, et al. Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology. 2004; 63 (7): 1324-1325.
39. Bosch J, Yusuf S, Pogue J, et al. Use of ramipril in preventing stroke: double blind randomised trial. BMJ. 2002; 324 (7339): 699-702.
40. Tzourio C, Anderson C, Chapman N, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med. 2003; 163 (9): 1069-1075.
41. Trenkwalder P,. The Study on COgnition and Prognosis in the Elderly (SCOPE) - recent analyses. J Hypertens. 2006; 24 (1): S107-S114.
42. Hanon O, Pequignot R, Seux ML, et al. Relationship between antihypertensive drug therapy and cognitive function in elderly hypertensive patients with memory complaints. J Hypertens. 2006; 24 (10): 2101-2107.
43. Konstam MA, Neaton JD, Dickstein K, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009; 374 (9704): 1840-1848.
44. Hogg K, Swedberg K, McMurray J,. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol. 2004; 43 (3): 317-327.
45. Lau HS, de Boer A, Beuning KS, Porsius A,. Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol. 1997; 50 (5): 619-625.